
Alpha Modus ($AMOD): The AI Retail Tech Challenger Taking on Rackspace, Cisco – and Winning Investor Confidence
Alpha Modus Corp. (Nasdaq: AMOD) is proving it's more than just another AI startup. In a year defined by aggressive patent enforcement, strategic licensing deals, and a bold $3 million personal investment from its CEO, the company is making waves across the tech and retail sectors alike—and investors are beginning to take notice.
From landmark lawsuits against giants like Cisco and Rackspace to rapid expansion of its fintech and AI-driven kiosk solutions, Alpha Modus is executing on a clear, aggressive playbook: monetize innovation, expand reach, and maximize shareholder value.
The Heart of the Battle: IP Enforcement and Patent Monetization
Alpha Modus isn't backing down from industry heavyweights. Its 7th IP enforcement action, filed June 24th against Rackspace (U.S. District Court, Western District of Texas), accuses the company of willful infringement on foundational patents involving Fibre Channel over Ethernet (FCoE) technology—critical for cloud and enterprise data infrastructure.
'We are unlocking value for shareholders by defending what we built—our technology, our vision, and our future,' said AMOD CEO William Alessi.
Rackspace now joins a growing list of companies—including Cisco Systems and Broadcom —facing similar claims from AMOD and its patent-holding affiliate, Alpha Modus Ventures. AMOD alleges unauthorized use of its patented data transport technologies, with potential damages expected to be significant.
CEO's Bold $3M Personal Investment: 'No Derivatives, No Dilution'
Just one day before the Rackspace announcement, CEO William Alessi doubled down on AMOD's future by pledging up to $3 million in personal capital to fund operations through the end of 2025. His move also included a swap of preferred stock for common shares, aligning his long-term interests directly with everyday shareholders.
'We've rejected every third-party derivative offer. This is about building real value—not dilution,' Alessi stated.
With a robust pipeline of enterprise contracts and new product rollouts, the company expects to reach positive cash flow by year-end.
Strategic Growth: From AI Media to Fintech Kiosks
AMOD's aggressive tech commercialization strategy is gaining traction, particularly through strategic partnerships that leverage its proprietary AI and retail media technology:
CashX Rollout with Genmega A nationwide reseller deal with ATM/kiosk leader Genmega gives AMOD a powerful distribution channel for its CashX AI-enabled payment terminals. The smart kiosks deliver retail ads, bill pay, mobile top-up, check cashing—and connect back to AMOD's patented retail tech stack.
VSBLTY Licensing & Integration Deal A new licensing agreement with VSBLTY Groupe Technologies (OTC: VSBGF), a leader in AI security and analytics, paves the way for a broader strategic alliance. The partnership could see AMOD's IP integrated into Shelf Nine's in-store retail media networks.
Settlement with Wakefern/Shelf Nine A recent legal settlement turned into opportunity: AMOD secured a perpetual licensing deal and opened the door to integrate with VSBLTY and Shelf Nine's network—validating AMOD's IP while accelerating its retail footprint.
Market Timing: AI in Retail Is Booming
With U.S. retail media spend projected to top $60 billion by 2025 and the global self-service kiosk market expected to double by 2030, AMOD is strategically positioned at the intersection of both megatrends.
Its combination of patented technology, scalable fintech hardware, and real-time AI-driven analytics positions the company to dominate the in-store retail transformation space —right as retailers double down on data, automation, and personalization.
Nasdaq Capital Market Uplisting in Sight
With fundamentals strengthening and revenue streams maturing, Alpha Modus has also applied to transfer its listing to the Nasdaq Capital Market, anticipating full compliance with exchange standards. Management continues to stress operational efficiency, avoiding variable-rate financing to protect shareholder value.
Bottom Line for Investors
Alpha Modus is no longer a hidden gem. Its aggressive IP enforcement, bold executive leadership, and real-world AI solutions in retail are beginning to converge in powerful ways. For investors looking for exposure to AI, fintech, IP monetization, and retail transformation, $AMOD is a small-cap with outsized potential.
As 2025 progresses, the company's performance in the courtroom and the marketplace alike may redefine how AI innovators create—and protect—value.
For More Information Visit Website: alphamodus.com
Disclosure listed on the CorporateAds website
Media Contact
Company Name: Alpha Modus Corp.
Contact Person: Investor Relations
Email: Send Email
Phone: (704) 252-5050
Address: 20311 Chartwell Center Dr Suite 1469
City: Cornelius
State: North Carolina
Country: United States
Website: https://alphamodus.com/

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
17 minutes ago
- CTV News
Sheri Willick Realty's pros and cons of condo ownership
Sheri Willick Realty's pros and cons of condo ownership SPONSORED: Sheri Willick has tips on buying and selling condominiums in Saskatchewan


Globe and Mail
an hour ago
- Globe and Mail
If You'd Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here's How Much You'd Have Today
Key Points Those who invested in Pfizer three years ago and hung on are not thrilled. They would have done much better with a simple S&P 500 index fund. Still, Pfizer today offers a fat dividend and plenty of growth potential. 10 stocks we like better than Pfizer › Wondering how well you'd have done if you'd invested in pharmaceutical giant Pfizer (NYSE: PFE) three years ago and hung on? Well, I'm afraid the answer isn't pretty: If you'd investing $1,000 in Pfizer on Aug. 8, 2022, hung on and reinvested dividends, that sum would have been worth $585 on Aug. 8, 2025. Ouch! For some context, during those same three years, the S&P 500 index of 500 of America's biggest companies averaged gains of roughly 17% per year, turning $1,000 into $1,615. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Here's some good news, though: Stock investors need to look forward much more than backward. Trailing returns are in the past. What matters most for current Pfizer investors and would-be Pfizer investors is how the company will perform from here on. And Pfizer's future is looking promising. Some investors have been disappointed in Pfizer when they've compared recent results to those from the past. But those past years were exceptional boom years thanks to Pfizer's COVID-19 vaccine and Paxlovid COVID-19 treatment. Those were in great demand, but demand has fallen. Others worry because some of Pfizer's big sellers, such as Eliquis, Ibrance, Inlyta, Xeljanz, Xtandi, and Vyndaqel, are coming off patent protection in the next few years. Pfizer has been planning for that, and investing in its pipeline, which features more than 100 active programs -- many of which are in oncology. Pfizer has also been getting additional approvals for its drugs, and it has been cutting its costs in an effort to boost profitability. Finally, Pfizer is a dividend-paying stock, with a whopping recent dividend yield of 7%. So as you invest in Pfizer and wait for its investments to pay off, you'll be rewarded. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025


CTV News
an hour ago
- CTV News
2031 housing goal: Ontario falling short?
Ontario's 2024 housing starts hit 94,700, including long-term care beds and student housing, but fell short of the 125,000 needed annually to reach its 1.5 million-home target by 2031.